CHAIN Awarded EuropaBio Membership
NOTTINGHAM, UK. — January 9th, 2019 — CHAIN has joined EuropaBio as a full member after placing runner-up in the Biotech SME Awards announced in November. As part of this membership, CHAIN gains access to EuropaBio’s network and will receive updates from working groups operating in diverse areas such as IP, regulatory policy and personalised […]
CHAIN Moves to MediCity
In November, CHAIN moved research base from the University of Nottingham into independent lab and office space at the art deco MediCity building in Nottingham. The move coincides with the Company’s expansion, hiring Lab Manager Claire Evans earlier this year to oversee the move and Junior Scientist Matthew Allen more recently to begin work on […]
CHAIN Features in Engineering Biology Explained
CHAIN features in a new explainer document on engineering biology from the UK Bioindustry Association (BIA) published today. Engineering Biology Explained discusses what these areas are all about, showcasing the important contributions made to these industries by UK bioscience companies and outlining the external environment required to ensure that these areas of innovation continue to benefit patients, […]
Superior and effective microbiome therapeutics
About us
CHAIN Biotechnology Ltd develops Clostridium-based microbial technology for high-value healthcare products. We produce novel 2nd generation live biotherapeutic products for chronic gut-related diseases.
Platform
Our Clostridium Assisted Drug Delivery (CADD™) platform is a targeted, robust and versatile method of delivering therapeutic bioactives to the gut in a safe, proven and affordable way.